Home > Cardiology > ACC 2023 > Dyslipidaemia > Inflammation stronger predictor of MACE than cholesterol levels

Inflammation stronger predictor of MACE than cholesterol levels

Presented by
Prof. Paul Ridker, Brigham and Women's Hospital, MA, USA
Conference
ACC 2023
Trial
Phase 3, PROMINENT, REDUCE-IT, STRENGTH
Doi
https://doi.org/10.55788/3da2b3db
A collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials (n=31,245) showed that residual inflammatory risk is a better predictor of future major adverse cardiovascular events (MACE), cardiovascular (CV) death, and all-cause mortality than residual cholesterol risk in statin-treated patients. Thus, targeting low-density lipoprotein cholesterol (LDL-C) alone is unlikely to completely reduce atherosclerotic risk.

Prof. Paul Ridker (Brigham and Women's Hospital, MA, USA) explained that the study aimed to determine the relative importance of high-sensitivity C-reactive protein (hsCRP) and LDL-C as determinants of risk for MACE, CV death, and all-cause death among patients receiving statins who were eligible for inclusion in these selected trials [1]. This could then resolve the clinically highly relevant question of whether to add a second LDL-lowering agent or rather an agent that inhibits inflammation to a statin.

Prof. Ridker and colleagues performed a collaborative analysis of patients with (a high risk of) atherosclerotic disease receiving contemporary statins who participated in the PROMINENT (NCT03071692), REDUCE-IT (NCT01492361), or STRENGTH (NCT02104817) trials. Included were 9,988, 8,179, and 13,078 participants from these respective studies, totalling 31,245 participants. Assessed were quartiles of increasing baseline hsCRP and LDL-C.

Comparing the highest (4th) quartile to the first (referent) quartile, residual inflammatory risk measured by hsCRP was significantly associated with:

  1. incident MACE (HR 1.31; 95% CI 1.20–1.43; P<0.0001);
  2. CV mortality (HR 2.68 95%; CI 2.22–3.23; P<0.0001); and
  3. all-cause mortality (HR 2.42 95%; CI 2.12–2.77; P<0.0001).

Residual cholesterol risk was not associated with MACE (HR 1.07; 95% CI 0.98–1.17; P=0.11). It was associated with CV death and all-cause death, but HRs were much lower: 1.27 (95% CI 1.07–1.50; P=0.0086) and 1.16 (95% CI 1.03–1.32; P=0.025), respectively.

In all 3 trials, patients with elevated hsCRP were at high CV risk irrespective of their LDL-C levels, Prof. Ridker concluded. So, which options are available to prescribe in addition to a statin? Prof. Ridker mentioned colchicine (0.5 mg) for patients with stable atherosclerosis and normal eGFR; bempedoic acid, which reduces both LDL-C and hsCRP; or SGLT2i and GLP1RAs, both of which have concomitant anti-inflammatory effects. “We believe the combined use of aggressive LDL-lowering and inflammation-inhibiting therapies will become standard of care for almost all atherosclerotic patients.”

  1. Ridker P, et al. Residual inflammatory risk in contemporary statin treated patients: A collaborative analyses of 31,197 participants in the PROMINENT, REDUCE-IT, and STRENGTH trials. Session 411-10, ACC Scientific Session 2023, 4–6 March, New Orleans, USA.

 

Copyright ©2023 Medicom Medical Publishers



Posted on